I’ve gone deep on my research. Over 40 years for this investment. Plus in-depth look at chemo.
The name Bisantrene has been used throughout development so there is no attempt to obfuscate. All the background trials are easy to find.
As for other biotechs, obfuscation is unfortunately common - both in naming (renaming) of drugs and vague reporting of results.
Biotech code of practice is weak and also ASX seem to be weak in their enforcement of it.
At least Dr Tillett has said he wants to lift reporting standards.
RAC Charts, page-927
-
- There are more pages in this discussion • 839 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.79 |
Change
0.000(0.00%) |
Mkt cap ! $304.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3900 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 580 | 1 |
View Market Depth
| Last trade - 09.43am 01/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
Day chart unavailable